期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 89, 期 -, 页码 442-466出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2014.10.034
关键词
Heat shock protein 90; Hsp90 C-Terminal inhibitors; Biphenyl; Structure-activity relationship; Breast cancer
资金
- NIH/NCI [CA120458]
- NSF [9512331]
- AIRC (Associazione Italiana Ricerca sul Cancro) [IG.11775]
- MIUR [PB.P05]
- CNR
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatment of cancer and neurodegenerative diseases. Current drug discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor. Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors. Structure activity relationship studies produced new derivatives that inhibit the proliferation of breast cancer cell lines at nanomolar concentrations, which corresponded directly with Hsp90 inhibition. (C) 2014 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据